• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Seagen Inc.

    12/14/23 8:40:55 AM ET
    $SGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGEN alert in real time by email
    S-8 POS 1 d593258ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on December 14, 2023

    Registration No. 333-273617

    Registration No. 333-240236

    Registration No. 333-232397

    Registration No. 333-226370

    Registration No. 333-212688

    Registration No. 333-204331

    Registration No. 333-197992

    Registration No. 333-188446

    Registration No. 333-176144

    Registration No. 333-168672

    Registration No. 333-148188

    Registration No. 333-56670

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-273617

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-240236

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-232397

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-226370

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-212688

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-204331

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-197992

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-188446

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-176144

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-168672

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-148188

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-56670

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SEAGEN INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   91-1874389

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    21823 30th Drive SE

    Bothell, Washington 98021

    (Address of Principal Executive Offices) (Zip Code)

    Amended and Restated 2007 Equity Incentive Plan

    Amended and Restated 2000 Employee Stock Purchase Plan

    2000 Directors’ Stock Option Plan, as Amended

    1998 Stock Option Plan

    (Full title of the plans)

    Margaret M. Madden, Esq.

    Vice President

    Seagen Inc.

    66 Hudson Boulevard East

    New York, New York 10001

    (Name and address of agent for service)

    (212) 733-2323

    (telephone number, including area code, of agent for service)

     

     

    Copies to:

    David K. Lam

    Zachary S. Podolsky

    Wachtell, Lipton, Rosen & Katz

    51 West 52nd Street

    New York, New York 10019

    (212) 403-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    These Post-Effective Amendments relate to the following Registration Statements on Form S-8 (each, a “Registration Statement” and collectively, the “Registration Statements”) previously filed by Seagen Inc., a Delaware corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”):

     

      •  

    Registration Statement on Form S-8 (File No. 333-273617), originally filed with the SEC on August 2, 2023, registering 5,190,000 shares of the Company’s Common Stock, par value $0.001 per share (“Shares”), issuable in connection with the Company’s Amended and Restated 2007 Equity Incentive Plan (the “Equity Incentive Plan”).

     

      •  

    Registration Statement on Form S-8 (File No. 333-240236), originally filed with the SEC on July 31, 2020, registering 6,000,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-232397), originally filed with the SEC on June 27, 2019, registering 1,000,000 Shares, issuable in connection with the Company’s Amended and Restated 2000 Employee Stock Purchase Plan (the “ESPP”).

     

      •  

    Registration Statement on Form S-8 (File No. 333-226370), originally filed with the SEC on July 26, 2018, registering 6,000,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-212688), originally filed with the SEC on July 26, 2016, registering 6,000,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-204331), originally filed with the SEC on May 20, 2015, registering 1,000,000 Shares, issuable in connection with the ESPP.

     

      •  

    Registration Statement on Form S-8 (File No. 333-197992), originally filed with the SEC on August 8, 2014, registering 4,500,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-188446), originally filed with the SEC on May 8, 2013, registering 4,000,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-176144), originally filed with the SEC on August 8, 2011, registering 700,000 Shares, issuable in connection with the ESPP.

     

      •  

    Registration Statement on Form S-8 (File No. 333-168672), originally filed with the SEC on August 9, 2010, registering 7,500,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-148188), originally filed with the SEC on December 19, 2007, registering (a) 5,000,000 Shares, issuable in connection with the Equity Incentive Plan and (b) 500,000 Shares, issuable in connection with the Company’s 2000 Directors’ Stock Option Plan, as amended (the “Directors’ Stock Option Plan”).

     

      •  

    Registration Statement on Form S-8 (File No. 333-56670), originally filed with the SEC on March 7, 2001, registering (a) 11,899,297 Shares, issuable in connection with the Company’s 1998 Stock Option Plan; (b) 3,000,000 Shares, issuable in connection with the 2000 Employee Stock Purchase Plan; and (c) 400,000 Shares, issuable in connection with the Directors’ Stock Option Plan.

    These Post-Effective Amendments are being filed in connection with the closing on December 14, 2023 of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of March 12, 2023 (the “Merger Agreement”), by and among Pfizer Inc., a Delaware corporation (“Parent”), Aris Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company. On December 14, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.


    As a result of the Merger, the Company has terminated all offerings of the Company’s securities pursuant to the Registration Statements. In accordance with undertakings made by the Company in each Registration Statement to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offerings, the Company hereby removes from registration all such securities of the Company registered pursuant to the Registration Statements that remain unsold and any plan interests that are unissued as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities and the effectiveness of each such Registration Statement is hereby terminated.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on December 14, 2023. No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

    SEAGEN INC.
    By:  

    /s/ Margaret M. Madden

      Name:   Margaret M. Madden
      Title:   Vice President
    Get the next $SGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGEN

    DatePrice TargetRatingAnalyst
    2/16/2023$140.00 → $175.00In-line → Outperform
    Evercore ISI
    2/16/2023$155.00 → $175.00Outperform → Strong Buy
    Raymond James
    2/6/2023$162.00 → $141.00Outperform → Market Perform
    SVB Securities
    11/21/2022$135.00Hold
    Truist
    10/11/2022$177.00 → $178.00Market Perform → Outperform
    BMO Capital Markets
    6/29/2022$220.00Outperform
    Raymond James
    6/24/2022$169.00Market Perform
    BMO Capital Markets
    2/16/2022$201.00 → $142.00Market Outperform
    JMP Securities
    More analyst ratings